Clinical Trials

DermatologicGastrointestinalGynecologicLymphoid

30 enrolled

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT05770544 2025-11-24

DETERMINE

CNSDermatologicLymphoidOther hematologic neoplasm

30 enrolled

Brain Neoplasms, Glioma, Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT01861938 2025-10-02

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Phase 2/3 Withdrawn

Melanoma, Neoplasm Metastasis

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

135 enrolled

Phase 2/3 Active not recruiting

Melanoma

NCT03470922 2025-09-09

RELATIVITY-047

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT04695977 2025-09-05

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

20 enrolled 18 charts

Melanoma

NCT04901988 2025-02-27

DETECTION

8 enrolled

Melanoma

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

200 enrolled

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT01088737 2019-08-13

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

60 enrolled

Melanoma, Hutchinson's Melanotic Freckle

NCT03552549 2019-07-24

SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)

126 enrolled 9 charts

DermatologicGenitourinaryMyeloidOther hematologic neoplasm

Melanoma

NCT02829775 2017-01-09

A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies

Phase 2/3 Completed

9 enrolled 7 charts

Carcinoma, Renal Cell, Melanoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02962947 2016-11-15

MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients

546 enrolled

Melanoma

NCT01729663 2015-09-02

Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients

108 enrolled

Melanoma

NCT01259284 2012-08-07

Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

2 enrolled 4 charts

Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Sarcoma, Urogenital Neoplasms, Colorectal Neoplasms

NCT00811200 2009-07-02

TORR

220 enrolled

Uveal Melanoma, Macular Degeneration, Melanoma, Retinal Diseases, Choroid Diseases

NCT00055562 2005-06-24

Study to Compare the Efficacy and Safety of Two CC-5013 Dose Regimens in Subjects With Metastatic Malignant Melanoma

Phase 2/3 Completed

274 enrolled